US Neurology Editor-in-Chief, Said Beydoun (Keck Medical Center of USC, University of Southern California, CA, USA), discusses emerging therapies for the management of myasthenia gravis.
- What have been the major findings of the MGTX randomised study of thymectomy in myasthenia gravis? (0:04)
- Which patients are most likely to benefit from thymectomy? (2:13)
- Which other emerging therapies seem promising in the treatment of myasthenia gravis? (3:27)
View Part 1 of this expert interview here.
Speaker disclosures: Said Beydoun has received research grants from Argenx, Catalyst and UCB, and is a consultant, advisory board member and speaker for Alexion.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Neuromuscular Diseases
Teresa Coelho, WCN 2021: New Therapies in Hereditary ATTR Amyloidosis – Tafamidis, Patisiran, Inotersen and Future Therapies
touchNEUROLOGY met with Dr Teresa Coelho (Unidade Clinica de Paramiloidose, Hospital de Santo Antonio, Porto, Portugal) to discuss new therapies for the treatment of hereditary ATTR amyloidosis. Hereditary ATTR amyloidosis is a progressive and fatal disorder caused by variant transthyretin deposition as amyloid. The interview discusses an overview of tafamidis, patisiran, and inotersen, and their […]
Giuseppe Lauria Pinter, WCN 2021: The Unfolded Protein Response in ALS: Results of a Phase 2 Trial
touchNEUROLOGY met up with Prof. Giuseppe Lauria Pinter (University of Milan, Milan, Italy) to discuss the efficacy and outcome measures of a phase 2 study investigating guanabenz for the treatment of amyotrophic lateral sclerosis. The abstract entitled: ‘The unfolded protein response in Amyotrophic lateral sclerosis: Results of a Phase 2 Trial’ was presented at the […]
Renato Mantegazza, EAN 2021: Challenges in the Treatment of Myasthenia Gravis
touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy) to discuss the challenges that arise in treating patients with myasthenia gravis. The abstract entitled: ‘Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results’ was presented at the 7th […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!